CTRI/2022/11/047688
Not yet recruiting
未知
High-throughput, affordable newborn screening for Inborn Errors of Metabolism using Tapestry
Algorithmic Biologics Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Algorithmic Biologics Private Limited
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects whose Guardians are willing to give written informed consent for study participation
- •Subjects who are ready to comply with the study related procedures
Exclusion Criteria
- •Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research on newborn screening for treatable neonatal and childhood diseasesprimary immunodeficiency, spinal muscular atrophyJPRN-UMIN000045633Tokyo Medical and Dental University
Recruiting
Not Applicable
establishing newborn screening program for metabolic disorders in Udupi DistrictHealth Condition 1: null- all newborns 48 hours old also includes,doctors nurses anganwadi workersCTRI/2017/09/009912Vision Group Science and Technology
Recruiting
Not Applicable
Establishment of expanded newborn screening system in Tokyo metropolitaSpiral Muscular Atrophy, Severe Combinede Immunodeficiency, Pompe Disease, Mucopolysaccharidosis type I &II, Fabry diseaseJPRN-UMIN000048900Department of Pediatrics, The Jikei University School of Medicine4,000
Not yet recruiting
Not Applicable
Genetic Newborn Screening for Rare Diseases within the Screen4Care Projectgenetic newborn screeningDRKS00033501niversitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen20,000
Recruiting
Not Applicable
Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3Familial Hemophagocytic Lymphohistiocytosis 2/3DRKS00028493niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)im Zentrum für Translationale Zellforschung200